Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.88 and traded as high as $1.08. Brainstorm Cell Therapeutics shares last traded at $1.08, with a volume of 42,883 shares.
Brainstorm Cell Therapeutics Price Performance
The firm has a market cap of $12.29 million, a price-to-earnings ratio of -0.32 and a beta of 0.28. The stock has a 50-day moving average price of $1.00 and a 200 day moving average price of $0.88.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). As a group, equities research analysts predict that Brainstorm Cell Therapeutics Inc. will post -3.01 earnings per share for the current year.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Copper’s Record Rally Highlights a Deeper Supply Problem
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
